Building independent research leaders in HIV-associated malignancies in Uganda

项目总结/摘要 自艾滋病毒广泛传播以来，艾滋病毒感染者的癌症发病率每年都在增加。 提供抗逆转录病毒疗法。癌症现在是艾滋病毒阳性者的主要死因， 诊断为HIV相关恶性肿瘤（HIVAM）后的生存率低于HIV阴性 癌症在世界各地。在艾滋病毒和病毒致癌基因流行率高的地区， 恶性肿瘤，如卡波西肉瘤，非霍奇金淋巴瘤和宫颈癌， 对艾滋病毒感染者健康的最大威胁;非艾滋病定义的癌症，如肝细胞癌 癌症、肺癌和肛门癌现在占艾滋病毒感染者的50%以上。癌症需要新的策略 在资源有限的情况下，艾滋病毒感染者的预防和治疗。 自2004年以来，弗雷德哈钦森癌症研究中心（FHCRC）与乌干达 乌干达坎帕拉的癌症研究所（UCI）进行艾滋病毒/艾滋病相关的研究，并制定新的癌症战略 治疗和预防。通过几个建立良好的培训赠款和强大的关系，与我们的 学术合作伙伴，华盛顿大学（UW）和Makerere大学（MU），我们已经培训了>300 艾滋病毒/艾滋病管理研究和护理的所有级别的个人。与学术界、政府和 乌干达的临床领导人发现，在进行艾滋病毒/艾滋病研究的能力方面仍然存在差距，特别是与艾滋病毒/艾滋病有关的研究。 初级调查员进行独立研究的能力。我们建议支持发展 乌干达艾滋病毒/艾滋病和疟疾研究领导人通过三个具体目标：1）扩大训练有素的研究骨干队伍 通过授予博士学位，重点是临床试验研究， 我们与Makerere大学健康科学学院（MakCHS）建立的计划; 2）提供有针对性的 培训，以促进以前的高级学位学员的成熟，以独立作为调查员， 3）加强研究技能，扩大乌干达研究人员的社区， HIVAM通过一个既定的同伴指导职业发展计划。拟议的培训活动 建立在我们目前的培训计划的经验，并将由一个有经验的和杰出的监督 该委员会代表来自美国和乌干达的艾滋病毒和肿瘤学研究领导者。

PROJECT SUMMARY / ABSTRACT The incidence of cancer among persons with HIV infection has increased annually since the widespread availability of antiretroviral therapy. Cancer is now a leading cause of death among HIV-positive persons, as survival after a diagnosis of an HIV-associated malignancy (HIVAM) is poorer compared with HIV-negative cancers across the world. In regions with a high prevalence of both HIV and viral oncogens, AIDS-defining malignancies such as Kaposi Sarcoma, non-Hodgkin lymphoma and cervical cancer present some of the largest threats to the health of HIV-infected individuals; non-AIDS defining cancers such at hepatocellular carcinoma, lung cancer and anal cancer now comprise >50% of HIVAM. New strategies are needed for cancer prevention and treatment among persons living with HIV in resource-limited settings. Since 2004, the Fred Hutchinson Cancer Research Center (FHCRC) has collaborated with the Uganda Cancer Institute (UCI) in Kampala, Uganda, to conduct research in HIVAM and develop new strategies for cancer treatment and prevention. Through several well-established training grants and strong relationships with our academic partners, the University of Washington (UW) and Makerere University (MU), we have trained >300 individuals in HIVAM research and care at all levels. Key informant interviews with academic, governmental and clinical leaders in Uganda find that gaps in the capacity to conduct HIVAM research persist, particularly related to junior investigators' abilities to conduct independent research. We propose to support the development of research leaders in HIVAM in Uganda through three Specific Aims: 1) Expand the cadre of trained research leaders in the field of HIVAM by conferring doctoral degrees with an emphasis on clinical trials research through our established program with the Makerere University College of Health Sciences (MakCHS); 2) Provide targeted training to facilitate the maturation of previous advanced degree trainees to independence as investigators in HIVAM in Uganda; 3) Strengthen the research skills and expand the community of Uganda investigators in HIVAM through an established Peer Mentoring Career Development program. The proposed training activities build on experiences with our current training programs and will be overseen by an experienced and outstanding committee representing leaders in HIV and oncology research from the US and Uganda.